Top

Published in:

01-11-2011 | Epidemiology

Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women

Authors: Biyun Qian, Hong Zheng, Herbert Yu, Kexin Chen

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Abstract

The relationship between IGF genotypes and phenotypes in breast tumors and their associations with breast cancer risk remain to be elucidated. Such information is especially scarce in Chinese women. To evaluate IGF-I and IGFBP-3 genotypes in relation to their phenotypes in local breast tissues and in association with breast cancer risk, we conducted a case–control study among Chinese women. The study recruited 403 breast cancer patients and 403 age-matched controls. Four single nucleotide polymorphisms (SNP) in the IGF-I gene (rs1520220, rs2946834, rs2195239, and rs7965399) and two SNPs of the IGFBP-3 gene (rs2854746 and rs2960436) with known correlations with their phenotypes in the circulation were genotyped using TaqMan assays. Fresh tumor samples from the same patients were analyzed with immunoassays for protein concentrations of IGF-I and IGFBP-3. Associations of breast cancer with these SNPs were examined using unconditional logistic regression. Correlations between IGF genotypes and phenotypes were determined with Wilcoxon rank-sum test. Of the six selected SNPs, only one IGF-I SNP (rs7965399) was associated with breast cancer risk in a recessive model (OR = 1.86; 95% CI: 1.04–3.32), and the association was more evident in patients who had menopause under age 50 or ER negative tumors. No associations were found between breast cancer and other three IGF-I and two IGFBP-3 SNPs. Patients with variant IGF-I or wild IGFBP-3 genotypes had higher peptide levels of IGF-I compared to those with wild IGF-I or variant IGFBP-3 genotypes. The selected IGF-I and IGFBP-3 SNPs did not show any strong evidence for being associated with breast cancer risk, but the genotypes were correlated with IGF-I phenotypes in tumor samples, suggesting possible influences of these SNPs on IGF-I activity in local tissues.

Moschos SJ, Mantzoros CS (2002) The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63(4):317–332PubMedCrossRef

Wood TL, Yee D (2000) Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer. J Mammary Gland Biol Neoplasia 5(1):1–5PubMedCrossRef

Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8(3):197–209PubMedCrossRef

Marshman E, Streuli CH (2002) Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4(6):231–239PubMedCrossRef

Hadsell DL, Bonnette SG (2000) IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia 5(1):19–30PubMedCrossRef

Laban C, Bustin SA, Jenkins PJ (2003) The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 14(1):28–34PubMedCrossRef

Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396PubMedCrossRef

Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88(5):828–832PubMedCrossRef

Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR, Berkel HJ, Zheng W (2002) Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 11(8):705–712PubMed

10.

Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353PubMedCrossRef

11.

Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos Santos Silva I, Peto J, Holly JM, Key TJ (2005) A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92(7):1283–1287PubMedCrossRef

12.

Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Boillot C, Rinaldi S, Llewellyn M, Chajes V, Clavel-Chapelon F et al (2005) Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev 14(10):2316–2325PubMedCrossRef

13.

Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17(12):1668–1675PubMedCrossRef

14.

Yu H, Li BD, Smith M, Shi R, Berkel HJ, Kato I (2001) Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat 70(2):117–122PubMedCrossRef

15.

Setiawan VW, Cheng I, Stram DO, Penney KL, Le Marchand L, Altshuler D, Kolonel LN, Hirschhorn J, Henderson BE, Freedman ML (2006) Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15(1):172–174PubMedCrossRef

16.

Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13(8):1290–1295PubMed

17.

Qiu LX, Yao L, Yuan H, Mao C, Chen B, Zhan P, Xue K, Zhang J, Hu XC (2010) IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls. Breast Cancer Res Treat 122(3):867–871

18.

Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F et al (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 3(7):e2578PubMedCrossRef

19.

Rohrbacher M, Risch A, Kropp S, Chang-Claude J (2005) The A(-336C) insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev 14(1):289–290PubMed

20.

Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P et al (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15(1):1–10PubMedCrossRef

21.

Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE et al (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15(10):1993–1997PubMedCrossRef

22.

Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V et al (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94(2):299–307PubMedCrossRef

23.

Wagner K, Hemminki K, Forsti A (2007) The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treat 104(3):233–248PubMedCrossRef

24.

Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, Byers T (2007) Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat 104(2):197–209PubMedCrossRef

25.

Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res 19(4): 519–523

26.

Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98(2):123–134PubMedCrossRef

27.

Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA (2007) Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9(1):R18PubMedCrossRef

28.

Diorio C, Brisson J, Berube S, Pollak M (2008) Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17(4):880–888PubMedCrossRef

29.

Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107(1):60–64PubMedCrossRef

30.

Wagner K, Hemminki K, Israelsson E, Grzybowska E, Soderberg M, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E et al (2005) Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92(2):133–140PubMedCrossRef

31.

Mu L, Katsaros D, Wiley A, Lu L, de la Longrais IA, Smith S, Khubchandani S, Sochirca O, Arisio R, Yu H (2009) Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res Treat 115(1):151–162PubMedCrossRef

32.

Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT, Zheng W (2007) Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 104(3):309–319PubMedCrossRef

33.

Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA (2007) IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinog 28(10):2154–2159

34.

Pechlivanis S, Wagner K, Chang-Claude J, Hoffmeister M, Brenner H, Försti A (2007) Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer. Cancer Detect Prev 31(5):408–416

35.

Feik E, Baierl A, Hieger B, Führlinger G, Pentz A, Stättner S, Weiss W, Pulgram T, Leeb G, Mach K, Micksche M, Gsur A (2010) Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control 21(1):91–97

36.

Terry KL, Tworoger SS, Gates MA, Cramer DW, Hankinson SE (2009) Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinog 30(12):2042–2046

Title: Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women
Authors: Biyun Qian
Hong Zheng
Herbert Yu
Kexin Chen
Publication date: 01-11-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1552-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

Detection of circulating tumor cells by RT-PCR significantly associated with poor prognosis in breast cancer

Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations

Re Panoff et al., Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation

Breast cancer risk assessment in women aged 70 and older

Keynote webinar | Spotlight on antibody–drug conjugates in cancer